TGFβ on the brain

Why Stanford, SRI are boosting TFGβ signaling to treat Parkinson’s

Against a checkered past of TGFβ signaling in preclinical models of Parkinson’s disease, a Stanford University team has provided new evidence that stimulating the pathway holds promise in the indication. Stanford and SRI International have made a small molecule activator of the pathway and are looking for a partner to help develop it in PD and other neurological indications.

In vitro and in vivo studies of the role of transforming

Read the full 691 word article

User Sign In